Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7341859 | 0.78 | MAOB (0.38) | KDM1AMAOBMAOABCHEADRA2B | |
| SCHEMBL4348712 | 0.78 | MAOB (0.38) | KDM1AMAOBMAOABCHEADRA2B | |
| SCHEMBL7947368 | 0.78 | MAOB (0.41) | KDM1AMAOBMAOABCHEADRA2B | |
| SCHEMBL6277987 | 0.73 | MAOB (0.34) | KDM1AMAOBMAOABCHEADRA2B | |
| SCHEMBL2146984 | 0.72 | KDM1A (0.42) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL5960895 | 0.72 | KDM1A (0.42) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL302419 | 0.72 | KDM1A (0.42) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| SCHEMBL29453777 | 0.72 | KDM1A (0.42) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL1970466 | 0.71 | KDM1A (0.41) | KDM1AMAOBMEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL27310401 | 0.71 | KDM1A (0.41) | KDM1AMAOBMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006014968-A2 | PROPARGYL NITROXYDES AND INDANYL NITROXIDES AND THEIR USE FOR THE TREATMENT OF NEUROLOGIC DISEASES AND DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025446-A1 | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
| WO-2005084205-A2 | DIAMINO THIAZOLOINDAN DERIVATIVES AND THEIR USE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025446-A1 | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders | CBR1, NR1H2, NR1H3 | KDM1A 2253/4885MAOB 996/4885MAOA 1371/4885 |
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | RTN3, RTN4, DRD4 | KDM1A 4198/4885MAOB 174/4885MAOA 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.